Abstract:Abstract The anthelmintic drug, Niclosamide, has a multitude of promising anticancer properties including inhibition of key signaling pathways involved in tumorigenesis, disruption of mitochondrial function, degradation of the overexpressed androgen receptor, and more. However, a key limitation of the clinical use of Niclosamide in cancer treatment is its low solubility and cellular uptake, which result in poor pharmacokinetic properties and dose-limiting GI toxicities at concentrations lower than the therapeutic threshold of the drug. To overcome this, we hypothesized that we could use amino acid conjugated niclosamide prodrugs to improve cellular uptake by creating a substrate of the PepT1 transport protein. The overexpression of the PepT1 transport protein that is involved in many hormonal cancers is being used to our advantage. Our study involved first synthesizing a group of niclosamide and niclosamide analogs conjugated with polar or nonpolar amino acids. Next, we conducted a Glycine-Sarcosine assay measuring changes in the uptake of the dipeptide glycyl-sarcosine (Gly-Sar). Our initial step was to examine if our conjugates could disrupt the absorption of Gly-Sar. The active conjugate will be tested whether they are substrates or inhibitors of the transporter. For the future, we have plans to determine the half-maximal inhibitory concentration (IC50) of niclosamide conjugates in various cancer cell lines and to quantify cleavage of the prodrugs intracellularly. Citation Format: Alaina C. McDonough, Jeffery Y. Cheng, Shabber Mohammed, Pui-Kai Li, Yangzom Bhutia. Design, synthesis, and evaluation of amino acid conjugated niclosamide prodrugs as a PepT1 substrate [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4479.

Antineoplastic agents 500. Narcistatin

Abstract 1818: Novel efficient isolation and water-soluble prodrug preparation of anti-cancer natural product narciclasine

Narciclasine, a novel topoisomerase I inhibitor, exhibited potent anti-cancer activity against cancer cells

Synthesis and Antitumor Activity of New Thiazole Nortopsentin Analogs

Directed Accumulation of Anticancer Depsipeptides by Characterization of Neoantimycins Biosynthetic Pathway and an NADPH-Dependent Reductase.

Nicotinamide Phosphoribosyltransferase Inhibitors, Design, Preparation, and Structure–Activity Relationship

Abstract 4479: Design, synthesis, and evaluation of amino acid conjugated niclosamide prodrugs as a PepT1 substrate

Synthesis, Characterization, and Biological Evaluation of Novel Naringenin Derivatives as Anticancer Agents

Design, Green Synthesis, and Anticancer Activity of Novel Nicotinonitrile Derivatives

Synthesis and anticancer assessment of some new 2-amino-3-cyanopyridine derivatives

2‐(1‐Methyl‐1H‐indazol‐5‐yl)‐N‐arylisonicotinamide Analogs: Synthesis, Anticancer Screening, SAR and ADMET Studies

Disodium Phosphate of Novel Pyrazole-Linked Norcantharidin Analogs: Design, Synthesis and Their Anticancer Evaluation

Efficient Synthesis of 8-Fluoro-10-methyl-3,4-dihydrobenzo[b][1,6]naphthyridine-2(1H)-carboxamides and Their Cytotoxic Activity

Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery

Design, Synthesis and Biological Evaluation of Nitrogen-Containing Macrocyclic Bisbibenzyl Derivatives As Potent Anticancer Agents by Targeting the Lysosome.

Norcantharidin Analogues — Synthesis and Evaluation of Growth Inhibition in a Panel of Selected Tumor-Cell Lines

One-pot two-step catalytic synthesis of 6-amino-2-pyridone-3,5-dicarbonitriles enabling anti-cancer bioactivity

Narciclasine induces colon carcinoma cell apoptosis by inhibiting the IL-17A/Act1/TRAF6/NF-κB signaling pathway

Design, Synthesis, and Anticancer Activity of Novel Methoxycyclohexyl Nicotinamides

Novel Nicotinoyl Pyrazoline Derivates Bearing N-methyl Indole Moiety As Antitumor Agents: Design, Synthesis and Evaluation

6-Benzylidene-2-[4-(pyridin-3-ylcarboxy)benzylidene]cyclohexanones: A novel cluster of tumour-selective cytotoxins